Artwork

Content provided by The Sunday Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Babson’s David Stein: “Succeeding where Theranos failed”

41:24
 
Share
 

Manage episode 389657150 series 1437555
Content provided by The Sunday Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The Sunday Times’ tech correspondent Danny Fortson brings on David Stein, chief executive of Babson Diagnostics, to talk about the importance of blood testing (4:49), why Babson is not Theranos (6:47), trying to compete with that idea (9:26), why they succeeded where Theranos failed (14:34), using a tiny amount of blood (18:23), fighting against the Theranos effect (24:37), being owned by a company they aim to disrupt (26:28), liquid biopsies (28:02), the new age of biological data (32:23), regulatory approval (37:09), and avoiding the spotlight (39:03).

Hosted on Acast. See acast.com/privacy for more information.

  continue reading

351 episodes

Artwork
iconShare
 
Manage episode 389657150 series 1437555
Content provided by The Sunday Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Sunday Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The Sunday Times’ tech correspondent Danny Fortson brings on David Stein, chief executive of Babson Diagnostics, to talk about the importance of blood testing (4:49), why Babson is not Theranos (6:47), trying to compete with that idea (9:26), why they succeeded where Theranos failed (14:34), using a tiny amount of blood (18:23), fighting against the Theranos effect (24:37), being owned by a company they aim to disrupt (26:28), liquid biopsies (28:02), the new age of biological data (32:23), regulatory approval (37:09), and avoiding the spotlight (39:03).

Hosted on Acast. See acast.com/privacy for more information.

  continue reading

351 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide